Offerings // Damora Therapeutics, Inc.

DMRA offering history

Every offering-related filing in Damora Therapeutics, Inc.’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 353 filings back to Jan 16, 2020.

Last executed offering

Feb 11, 2026

424B5 — priced deal (shares or notes)

Last registration (announced)

Feb 10, 2026

S-3ASR — capacity, not a sale

Executed, last 12 months

424B pricings + 8-K 3.02 sales

Registered, last 12 months

S-1/S-3/F-series registrations

Date	Filing		What it means
Aug 12, 2026	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Feb 11, 2026	424B5 →	EXECUTED	Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)
Feb 10, 2026	S-3ASR →	REGISTERED	Automatic shelf registration — effective immediately (large filers)
Feb 10, 2026	424B5 →	EXECUTED	Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)
Jan 6, 2026	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Dec 31, 2025	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Dec 23, 2025	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Dec 16, 2025	S-3 →	REGISTERED	S-3 registration — capacity to sell shares, not a sale yet
Nov 10, 2025	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Oct 7, 2024	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Mar 9, 2023	424B5 →	EXECUTED	Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)
Feb 18, 2022	424B5 →	EXECUTED	Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)
Nov 12, 2021	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Nov 4, 2021	S-3 →	REGISTERED	S-3 registration — capacity to sell shares, not a sale yet
Oct 30, 2020	424B4 →	EXECUTED	Final prospectus — offering priced (typical for IPOs and marketed share deals)
Oct 28, 2020	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Oct 22, 2020	S-1/A →	REGISTERED	S-1/A registration — capacity to sell shares, not a sale yet
Oct 7, 2020	S-1 →	REGISTERED	S-1 registration — capacity to sell shares, not a sale yet

DMRA offering-related filings from SEC EDGAR, newest first (capped at 40). Each links to the original document.

Two honest limits. (1) A 424B takedown can price shares or notes — EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.

Is a shelf active now? →Do they need money? →Red flags →Full DMRA workspace →

DMRA offering FAQ

When did DMRA last execute an offering?

Per SEC filings, Damora Therapeutics, Inc.'s most recent priced offering document is a 424B5 filed 2026-02-11. Note a 424B takedown can price shares or notes (debt) — the linked document says which.

When did DMRA last announce or register an offering?

The most recent registration is a S-3ASR filed 2026-02-10. A registration is capacity to sell shares — not a sale.

Does an offering always mean dilution?

Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.

Free to use. No account, no card.